To print: Select File and then Print from your browser's menu

Title: Continuation Treatment with Escitalopram Effective in Preventing Relapse Into An Episode Of Major Depressive Disorder

URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&dopt=Abstract&list_uids=14744167

J Clin Psychiatry 2004;65:44-49. "Escitalopram continuation treatment prevents relapse of depressive episodes"
02/25/2004 09:25:00 AM
By Emma Hitt, PhD

Continuation treatment with escitalopram, a serotonin reuptake inhibitor, is effective in preventing relapse into an episode of major depressive disorder, new research suggests. The antidepressant efficacy of escitalopram has been previously demonstrated in acute (8-week) trials in which both escitalopram and citalopram were compared with placebo. However, current antidepressant guidelines suggest 4 to 6 months of continuation treatment to prevent relapse of depression following symptom resolution. To investigate the efficacy and safety of continuing escitalopram treatment, Mark Hyman Rapaport, MD, with the Cedars-Sinai Medical Center, Los Angeles, California, United States and colleagues conducted an 8-week open-label study in which all patients received escitalopram (10-20 mg/day). Participants included 502 adult patients diagnosed with DSM-IV major depressive disorder who had completed 8 weeks of randomised double-blind treatment with escitalopram, citalopram, or placebo. They were then entered an 8-week flexible-dose, open-label phase in which all patients received escitalopram (10-20 mg/day). Patients who responded to the open-label phase of treatment (12 or less on the Montgomery-Asberg Depression Rating Scale [MADRS]) were then randomly assigned in a 2:1 ratio to escitalopram (at the dose each patient was receiving at the end of the open-label phase) or placebo for a further 36 weeks of double-blind treatment. A total of 274 evaluable subjects entered the double-blind treatment phase, with 93 receiving placebo and 181 receiving escitalopram. Time to depression relapse was significantly longer ([P = .013) and the cumulative rate of relapse was significantly lower in patients who received escitalopram (26%) versus those receiving placebo (40%); (hazard ratio = 0.56; P = .01). In addition, patients receiving escitalopram had significantly lower depression ratings than those of placebo-treated patients. The researchers note that escitalopram continuation treatment was safe and well tolerated. Discontinuation rates due to adverse events were 7% for the placebo group compared to 4% in those receiving escitalopram. "The present results extend previously reported observations from acute treatment trials and suggest that continued treatment with escitalopram is safe and effective, " Dr. Rapaport and colleagues conclude. "In this trial, escitalopram treatment led to the consolidation of acute treatment response and the prevention of relapse of depressive episodes," they add.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&dopt=Abstract&list_uids=14744167

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.